Treatsma website reaches national news in Bhutan
Treatsma website reaches national news in Bhutan.
Update on Roche’s SMA global clinical development programme: New global combination study to begin in early 2022
We are pleased to share with you the initiation of MANATEE, a new global Phase 2/3 clinical study that aims to evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth in combination with risdiplam, in Spinal Muscular Atrophy (SMA).
Living with SMA – Hitting Our Fourties
TreatSMA Trustee Andi Thornton speaks with SMA UK Trustee Toby Mildon about mental health, treatments, University and work, health care and much more
New trial announced by Biogen
New Clinical Study Planned to Evaluate the Potential Benefit of an Investigational Higher Dose of Nusinersen in People with SMA Previously Treated with Evrysdi® (risdiplam)
SMA UK put out a community survey
SMA UK has put out a community survey asking for people’s views on what services and activities they should focus on in the future. You can respond to their survey here https://www.surveymonkey.co.uk/r/SMAUKnext
Lianne joins the team
TreatSMA are extremely happy to announce that Lianne Harris has joined the team as a volunteer to assist with Fundraising and Events Co-ordination.
TreatSMA are now listed on AmazonSmile
We are now listed as a charity on Amazon Smile. By choosing us as your selected charity Amazon will donate 0.5% of the net purchase price (excluding VAT, returns and shipping fees) of eligible purchases to us. You can set…
Survey for Changing Places International
Ross Hovey (a friend of TreatSMA) is the co-founder of Changing Places International whose aim is to set a global standard for fully accessible toilets.